Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Eur J Med Chem ; 70: 111-9, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-24141201

RESUMO

Chromenopyrazolediones have been designed and synthesized as anticancer agents using the multi-biological target concept that involves quinone cytotoxicity and cannabinoid antitumor properties. In cell cytotoxicity assays, these chromenopyrazolediones have antiproliferative activity against human prostate cancer and hepatocellular carcinoma. It has been shown that the most potent, derivative 4 (PM49), inhibits prostate LNCaP cell viability (IC50 = 15 µM) through a mechanism involving oxidative stress, PPARγ receptor and partially CB1 receptor. It acts on prostate cell growth by causing G0/G1 phase arrest and triggering apoptosis as assessed by flow cytometry measurements. In the in vivo treatment, compound 4 at 2 mg/kg, blocks the growth of LNCaP tumors and reduces the growth of PC-3 tumors generated in mice. These studies suggest that 4 is a good potential anticancer agent against hormone-sensitive prostate cancer.


Assuntos
Antineoplásicos/farmacologia , Canabinoides/farmacologia , Carcinoma Hepatocelular/tratamento farmacológico , Neoplasias Hepáticas/tratamento farmacológico , Neoplasias da Próstata/tratamento farmacológico , Quinonas/farmacologia , Animais , Antineoplásicos/síntese química , Antineoplásicos/química , Canabinoides/síntese química , Canabinoides/química , Carcinoma Hepatocelular/patologia , Linhagem Celular Tumoral , Proliferação de Células/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Relação Dose-Resposta a Droga , Ensaios de Seleção de Medicamentos Antitumorais , Humanos , Neoplasias Hepáticas/patologia , Masculino , Camundongos , Estrutura Molecular , Neoplasias da Próstata/patologia , Quinonas/síntese química , Quinonas/química , Relação Estrutura-Atividade
2.
World J Gastroenterol ; 17(34): 3899-911, 2011 Sep 14.
Artigo em Inglês | MEDLINE | ID: mdl-22025878

RESUMO

AIM: To evaluate the efficacy and the safety of azathioprine (AZA) and buthionine sulfoximine (BSO) by localized application into HepG2 tumor in vivo. METHODS: Different hepatoma and colon carcinoma cell lines (HepG2, HuH7, Chang liver, LoVo, RKO, SW-48, SW-480) were grown in minimal essencial medium supplemented with 10% fetal bovine serum and 1% antibiotic/antimycotic solution and maintained in a humidified 37 °C incubator with 5% CO2. These cells were pretreated with BSO for 24 h and then with AZA for different times. We examined the effects of this combination on some proteins and on cellular death. We also studied the efficacy and the safety of AZA (6 mg/kg per day) and BSO (90 mg/kg per day) in HepG2 tumor growth in vivo using athymic mice. We measured safety by serological markers such as aminotransferases and creatine kinase. RESULTS: The in vitro studies revealed a new mechanism of action for the AZA plus BSO combination in the cancer cells compared with other thiopurines (6-mercaptopurine, 6-methylmercaptopurine, 6-thioguanine and 6-methylthioguanine) in combination with BSO. The cytotoxic effect of AZA plus BSO in HepG2 cells resulted from necroptosis induction in a mitochondrial-dependent manner. From kinetic studies we suggest that glutathione (GSH) depletion stimulates c-Jun amino-terminal kinase and Bax translocation in HepG2 cells with subsequent deregulation of mitochondria (cytochrome c release, loss of membrane potential), and proteolysis activation leading to loss of membrane integrity, release of lactate dehydrogenase and DNA degradation. Some of this biochemical and cellular changes could be reversed by N-acetylcysteine (a GSH replenisher). In vivo studies showed that HepG2 tumor growth was inhibited when AZA was combined with BSO. CONCLUSION: Our studies suggest that a combination of AZA plus BSO could be useful for localized treatment of hepatocellular carcinoma as in the currently used transarterial chemoembolization method.


Assuntos
Antimetabólitos Antineoplásicos , Azatioprina , Butionina Sulfoximina , Carcinoma Hepatocelular/tratamento farmacológico , Linhagem Celular Tumoral/efeitos dos fármacos , Neoplasias do Colo/tratamento farmacológico , Neoplasias Hepáticas/tratamento farmacológico , Animais , Antimetabólitos Antineoplásicos/farmacologia , Antimetabólitos Antineoplásicos/uso terapêutico , Apoptose/efeitos dos fármacos , Azatioprina/farmacologia , Azatioprina/uso terapêutico , Butionina Sulfoximina/farmacologia , Butionina Sulfoximina/uso terapêutico , Bovinos , Sobrevivência Celular/efeitos dos fármacos , Quimioterapia Combinada , Humanos , Camundongos , Camundongos Nus , Transplante de Neoplasias
3.
Cytokine ; 54(3): 330-7, 2011 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-21474332

RESUMO

Capsaicin (8-methyl-N-vanillyl-6-nonenamide), a constituent of green and red peppers, has been linked with suppression of tumorigenesis through a mechanism that is not well understood. In the present study, we examined the effects of capsaicin on the production of the cytokine interleukin (IL)-6 by PC-3 cells at both protein and mRNA levels which were evaluated by ELISA and real-time PCR, respectively. Capsaicin-treated PC-3 cells increased the synthesis and secretion of IL-6 which was abrogated by the transient receptor potential vanilloid receptor subtype 1 (TRPV1) antagonist capsazepine, as well as by inhibitors of PKC-α, phosphoinositol-3 phosphate kinase (PI-3K), Akt and extracellular signal-regulated protein kinase (ERK). We analyzed the role of capsaicin in the tumor necrosis factor (TNF)-α secretion by PC-3 cells which was increased at shorter times than IL-6 production. Furthermore, incubation of PC-3 cells with an anti-TNF-α antibody blocked the capsaicin-induced IL-6 secretion. These results raise the possibility that capsaicin-mediated IL-6 increase in prostate cancer PC-3 cells is regulated at least in part by TNF-α secretion and signaling pathway involving Akt, ERK and PKC-α activation.


Assuntos
Capsaicina/farmacologia , Interleucina-6/metabolismo , Neoplasias da Próstata/metabolismo , Capsaicina/análogos & derivados , Carcinoma/metabolismo , Linhagem Celular Tumoral , Sobrevivência Celular , Ensaio de Imunoadsorção Enzimática/métodos , MAP Quinases Reguladas por Sinal Extracelular/metabolismo , Humanos , Masculino , Fosfatidilinositol 3-Quinases/metabolismo , Transdução de Sinais , Canais de Cátion TRPV/metabolismo , Fator de Necrose Tumoral alfa/metabolismo
4.
J Immunotoxicol ; 6(4): 249-56, 2009 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-19908944

RESUMO

In the present study, we have investigated the effect of the cannabinoid R+ methanandamide (MET) in the androgen-resistant prostate cancer PC3 cells. MET induced a dose-dependent decrease in PC3 cell viability as well as a dose-dependent increase in the secretion of the cytokine IL-6. Looking deeper into the mechanisms involved, we found that MET-induced de novo synthesis of the lipid mediator ceramide that was blocked by the ceramide synthase inhibitor Fumonisin B1. Pre-incubation of cells with the cannabinoid receptor CB2 antagonist SR 144528 (SR2), but not the CB1 antagonist Rimonabant or the TRPV1 antagonist capsazepine, partially prevented the anti-proliferative effect, the ceramide accumulation, and the IL-6-induced secretion, suggesting a CB2 receptor-dependent mechanism. Fumonisin B1 did not have any effect in the IL-6 secretion increase induced by MET. However, even an incomplete down-regulation of (i.e., not a total silencing of) ceramide kinase expression by specific siRNA prevented the MET-induced IL-6 secretion. These results suggest that MET regulates ceramide metabolism in prostate PC3 cells which is involved in cell death as well as in IL-6 secretion. Our findings also suggest that CB2 agonists may offer a novel approach in the treatment of prostate cancer by decreasing cancer epithelial cell proliferation. However, the interaction of prostate cancer cells with their surrounding, and in particular with the immune system in vivo, needs to be further explored.


Assuntos
Adenocarcinoma/tratamento farmacológico , Antineoplásicos/farmacologia , Ácidos Araquidônicos/farmacologia , Interleucina-6/metabolismo , Neoplasias da Próstata/tratamento farmacológico , Adenocarcinoma/metabolismo , Apoptose/efeitos dos fármacos , Canfanos/farmacologia , Linhagem Celular Tumoral , Proliferação de Células/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Ceramidas/biossíntese , Ensaios de Seleção de Medicamentos Antitumorais , Inativação Gênica , Humanos , Masculino , Fosfotransferases (Aceptor do Grupo Álcool)/genética , Neoplasias da Próstata/metabolismo , Pirazóis/farmacologia , RNA Interferente Pequeno/genética , Receptor CB2 de Canabinoide/antagonistas & inibidores , Receptor CB2 de Canabinoide/efeitos dos fármacos , Receptor CB2 de Canabinoide/metabolismo , Transfecção
5.
FEBS Lett ; 583(1): 141-7, 2009 Jan 05.
Artigo em Inglês | MEDLINE | ID: mdl-19059400

RESUMO

In this study, capsaicin (trans-8-methyl-N-vanillyl-6-nonenamide) induced an increase in the cell viability of the androgen-responsive prostate cancer LNCaP cells, which was reversed by the use of the TRPV1 antagonists capsazepine, I-RTX and SB 366791. In further studies we observed that capsaicin induced a decrease in ceramide levels as well as Akt and Erk activation. To investigate the mechanism of capsaicin action we measured androgen (AR) receptor levels. Capsaicin induced an increase in the AR expression that was reverted by the three TRPV1 antagonists. AR silencing by the use of siRNA, as well as blocking the AR receptor with bicalutamide, inhibited the proliferative effect of capsaicin.


Assuntos
Capsaicina/farmacologia , Capsicum/química , Proliferação de Células/efeitos dos fármacos , Próstata/efeitos dos fármacos , Receptores Androgênicos/biossíntese , Anilidas/farmacologia , Capsaicina/análogos & derivados , Linhagem Celular Tumoral , Sobrevivência Celular/efeitos dos fármacos , Cinamatos/farmacologia , Diterpenos/farmacologia , Inativação Gênica , Humanos , Masculino , Quinases de Proteína Quinase Ativadas por Mitógeno/metabolismo , Fosfatidilinositol 3-Quinases/metabolismo , Próstata/enzimologia , Próstata/metabolismo , RNA Interferente Pequeno/genética , Receptores Androgênicos/genética , Canais de Cátion TRPV/antagonistas & inibidores
6.
Biochem Biophys Res Commun ; 372(4): 785-91, 2008 Aug 08.
Artigo em Inglês | MEDLINE | ID: mdl-18533110

RESUMO

The effect of capsaicin, main pungent ingredient of hot chilli peppers, in the gene expression profile of human prostate PC-3 cancer cells has been analyzed using a microarray approach. We identified 10 genes that were down-regulated and five genes that were induced upon capsaicin treatment. The data obtained from microarray analysis were then validated using quantitative real-time PCR assays and Western blot analysis. The most remarkable change was the up-regulation of GADD153/CHOP, an endoplasmic reticulum stress-regulated gene. Activation of GADD153/CHOP protein was corroborated by immunofluorescence and Western blot. We then tested the contribution of GADD153/CHOP to protection against capsaicin-induced cell death using RNA interference. Blockage of GADD153/CHOP expression by small interfering RNA, significantly reduced capsaicin-induced cell death in PC-3 cells. Taken together, these results suggested that capsaicin induces the antiproliferative effect through a mechanism facilitated by ER stress in prostate PC-3 cells.


Assuntos
Antineoplásicos/farmacologia , Capsaicina/farmacologia , Retículo Endoplasmático/efeitos dos fármacos , Expressão Gênica/efeitos dos fármacos , Próstata/efeitos dos fármacos , Fator de Transcrição CHOP/genética , Apoptose/genética , Proliferação de Células/efeitos dos fármacos , Retículo Endoplasmático/metabolismo , Humanos , Masculino , Análise de Sequência com Séries de Oligonucleotídeos , Próstata/metabolismo , Interferência de RNA , Fator de Transcrição CHOP/metabolismo
7.
Eur J Pharmacol ; 584(2-3): 237-45, 2008 Apr 28.
Artigo em Inglês | MEDLINE | ID: mdl-18343365

RESUMO

During the past decades, intense attention has been focused on the anti-tumor properties of marine compounds which some of them have been revealed as potent apoptotic inducers. In the present work, we studied the mechanism of action of a new compound, Spisulosine (ES-285), isolated from the sea mollusc Spisula polynyma, in the prostate tumor PC-3 and LNCaP cell lines. Spisulosine inhibited cell proliferation with an IC50 of 1 microM in both cell lines, although it was more effective in the androgen-independent PC-3 cells. The anti-proliferative effect induced by Spisulosine in prostate cells was independent of peroxisome proliferator activated receptor gamma (PPARgamma) and phosphatidylinositol 3-kinase/(PI3K/Akt), Jun N-terminal kinase (JNK), p38 or classical protein kinase C (PKCs) pathways, as it was inferred from the results obtained with specific inhibitors of these routes. However, Spisulosine treatment of prostate cells induced an increase in the intracellular ceramide levels, that was totally blocked by the ceramide synthase inhibitor Fumonisin B1, indicating that the ceramide accumulation came from the de novo biosynthesis. Spisulosine also induced in both PC-3 and LNCaP cells, an activation of the atypical PKC isoform, PKCzeta, which is one of the target proteins of ceramide. These results indicate that the marine compound Spisulosine inhibits the growth of the prostate PC-3 and LNCaP cells through intracellular ceramide accumulation and PKCzeta activation.


Assuntos
Antineoplásicos/farmacologia , Ceramidas/metabolismo , Ativadores de Enzimas/farmacologia , Lipídeos/farmacologia , Neoplasias da Próstata/dietoterapia , Neoplasias da Próstata/patologia , Proteína Quinase C/metabolismo , Antineoplásicos/uso terapêutico , Morte Celular/efeitos dos fármacos , Linhagem Celular Tumoral , Proliferação de Células/efeitos dos fármacos , Relação Dose-Resposta a Droga , Ativação Enzimática , Ativadores de Enzimas/uso terapêutico , Inibidores Enzimáticos/farmacologia , Humanos , Concentração Inibidora 50 , Lipídeos/uso terapêutico , Masculino , Oxirredutases/antagonistas & inibidores , Oxirredutases/metabolismo , Neoplasias da Próstata/enzimologia , Neoplasias da Próstata/metabolismo , Proteína Quinase C/antagonistas & inibidores
8.
Apoptosis ; 12(11): 2013-24, 2007 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-17828457

RESUMO

Numerous studies have recently focused on the anticarcinogenic, antimutagenic, or chemopreventive activities of the main pungent component of red pepper, capsaicin (N-vanillyl-8-methyl-1-nonenamide). We have previously shown that, in the androgen-independent prostate cancer PC-3 cells, capsaicin inhibits cell growth and induces apoptosis through reactive oxygen species (ROS) generation [Apoptosis 11 (2006) 89-99]. In the present study, we investigated the signaling pathways involved in the antiproliferative effect of capsaicin. Here, we report that capsaicin apoptotic effect was mediated by ceramide generation which occurred by sphingomyelin hydrolysis. Using siRNA, we demonstrated that N-SMase expression is required for the effect of capsaicin on prostate cell viability. We then investigated the role of MAP kinase cascades, extracellular signal-regulated protein kinase (ERK), c-Jun N-terminal kinase (JNK), and p38 MAPK, in the antiproliferative effect of capsaicin, and we confirmed that capsaicin could activate ERK and JNK but not p38 MAPK. Pharmacological inhibition of JNK kinase, as well as inhibition of ROS by the reducing agent N-acetylcysteine, prevented ceramide accumulation and capsaicin-induced cell death. However, inhibition of ceramide accumulation by the SMase inhibitor D609 did not modify JNK activation. These data reveal JNK as an upstream regulator of ceramide production. Capsaicin-promoted activation of ERK was prevented with all the inhibitors tested. We conclude that capsaicin induces apoptosis in PC-3 cells via ROS generation, JNK activation, ceramide accumulation, and second, ERK activation.


Assuntos
Apoptose/efeitos dos fármacos , Capsaicina/farmacologia , Ceramidas/metabolismo , Proteínas Quinases JNK Ativadas por Mitógeno/metabolismo , Próstata/efeitos dos fármacos , Esfingomielina Fosfodiesterase/fisiologia , Linhagem Celular , Ativação Enzimática/efeitos dos fármacos , Humanos , Células Jurkat , Masculino , Próstata/citologia , Próstata/enzimologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...